Planning for the Future: Family and Inheritance

When you receive a PALB2 diagnosis, your perspective on the future often shifts. Beyond your own health, you may find yourself thinking about your children or the children you hope to have. Understanding the genetics of inheritance is not just about numbers; it is about having the information you need to make the best decisions for your family’s future.

The 50% Rule: Passing on the Mutation

Because most PALB2 carriers have a heterozygous mutation (one mutated copy and one working copy), every time you have a child, each pregnancy is an independent event with a 50% chance that child will inherit the PALB2 mutation ^[1].

• If they inherit the mutation: They will be carriers, just like you. They will have the same increased risks for certain adult-onset cancers. Because these risks are primarily adult-onset, childhood surveillance is not needed; predictive testing and surveillance are typically planned for adulthood ^[2].
• If they do not inherit the mutation: They cannot pass it on to their own children. Their baseline risk is reduced, though family history of cancer or other genetic factors may still warrant screening outside of the PALB2 gene ^[1].

It is important to remember that inheriting one copy of the mutation does not cause childhood illness. A child with a single PALB2 mutation typically grows and develops just like any other child ^[2].

The Option of Partner Testing

While your status alone determines if a child will be a carrier, it takes two carriers to have a child with a much more serious condition called Fanconi Anemia Type N (FA-N).

If your reproductive partner also has a PALB2 mutation—even if they have no family history of cancer—every pregnancy has a 25% chance (1 in 4) of resulting in a child who inherits the mutation from both parents ^[3]. This is known as biallelic inheritance. Because of this risk, it is an option to discuss with a genetics or reproductive specialist that the partners of PALB2 carriers undergo genetic testing when biological children are planned ^[4][5].

If both partners carry pathogenic variants, there is a 50% chance the child inherits one mutation (heterozygous) and a 25% chance they inherit neither.

Understanding Fanconi Anemia Type N (FA-N)

Fanconi Anemia is a rare but severe “genomic instability” disorder. There are many types of Fanconi Anemia, but Type N (caused by PALB2) is known for being particularly aggressive and appearing very early in life ^[3].

Children born with FA-N often face significant health challenges from birth or early childhood:

• Congenital Abnormalities: Many children have physical signs such as small head size (microcephaly), short stature, skeletal differences, or skin pigmentation changes ^[3][6].
• Bone Marrow Failure: The “DNA repair crew” in these children is completely broken. Over time, their bone marrow stops being able to produce enough red blood cells, white blood cells, and platelets ^[3][7]. This can lead to severe fatigue, frequent infections, and dangerous bleeding.
• Early-Onset Cancers: Unlike the adult-onset cancers seen in carriers, children with FA-N are at a very high risk for specific “embryonal” tumors. These include Wilms tumor (a kidney cancer), medulloblastoma (a brain tumor), and neuroblastoma ^[8][3]. They also have a significantly higher risk of developing Acute Myeloid Leukemia (AML) at a very young age ^[8].

Why Treatment for FA-N is Specialized

Treating a child with FA-N is not like treating other pediatric cancers. Because every cell in their body lacks the ability to repair DNA, they are extremely sensitive to the very things used to fight cancer: chemotherapy and radiation ^[9].

Standard doses of these treatments can be toxic or even fatal to a child with FA-N ^[9]. If a child is diagnosed with this condition, they must be managed by a highly specialized team at a Fanconi Anemia center. While a Hematopoietic Stem-Cell Transplant (HSCT) can be potentially curative for the bone marrow failure, it does not reverse congenital abnormalities or eliminate all solid-tumor risk. This procedure must be performed using “reduced-intensity” protocols that protect the child’s fragile cells ^[9][10].

Proactive Options for Your Family

The goal of sharing this information is not to cause fear, but to highlight the options available to you. Modern reproductive technology allows you to address the risk of passing on a PALB2 mutation or facing an FA-N diagnosis.

• Preimplantation Genetic Testing (PGT-M): If you choose to use In Vitro Fertilization (IVF), scientists can test embryos for the specific PALB2 mutation before they are implanted in the uterus ^[11]. This allows you to choose to transfer only embryos that are not carriers, or those that have only one copy of the mutation and will not have FA-N ^[12][13]. Note that PGT-M requires IVF, may not produce a transferable embryo, and selecting a noncarrier embryo involves personal values.
• Prenatal Diagnosis: If you are already pregnant, you can choose to have a Chorionic Villus Sampling (CVS) or amniocentesis to determine if the fetus has inherited one or two copies of the mutation ^[14]. Testing a fetus for an adult-onset predisposition requires careful genetic counseling.
• Donor Options: Some families choose to use donor eggs or donor sperm from an individual who has tested negative for PALB2 mutations, which primarily eliminates the risk of biallelic FA-N; if you remain the biological parent, your child can still inherit your variant unless your gamete is not used ^[15].

Every path forward is valid. Whether you choose to test your partner, pursue IVF with PGT-M, or proceed with natural conception and testing later, your genetic counselor is there to support your values and your vision for your family ^[16].